FY2019 EPS Estimates for TAIWAN LIPOSOME/S (TLC) Reduced by Analyst
TAIWAN LIPOSOME/S (NASDAQ:TLC) – Stock analysts at Cantor Fitzgerald cut their FY2019 EPS estimates for TAIWAN LIPOSOME/S in a research note issued to investors on Monday, April 8th. Cantor Fitzgerald analyst M. Lillis now forecasts that the company will post earnings of ($1.16) per share for the year, down from their prior forecast of ($0.92). Cantor Fitzgerald has a “Buy” rating and a $11.00 price objective on the stock.
A number of other brokerages have also weighed in on TLC. Zacks Investment Research lowered TAIWAN LIPOSOME/S from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. Laidlaw assumed coverage on TAIWAN LIPOSOME/S in a research report on Monday, December 17th. They set a “buy” rating and a $11.00 price objective on the stock. Janney Montgomery Scott assumed coverage on TAIWAN LIPOSOME/S in a research report on Monday, December 17th. They set a “buy” rating on the stock. Finally, HC Wainwright assumed coverage on TAIWAN LIPOSOME/S in a research report on Monday, December 17th. They set a “buy” rating and a $9.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $10.33.
An institutional investor recently bought a new position in TAIWAN LIPOSOME/S stock. Millennium Management LLC bought a new position in shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 109,500 shares of the company’s stock, valued at approximately $602,000. Millennium Management LLC owned 0.34% of TAIWAN LIPOSOME/S at the end of the most recent quarter. 2.17% of the stock is currently owned by institutional investors.
TAIWAN LIPOSOME/S Company Profile
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.
See Also: What is the Dividend Aristocrat Index?
Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.